Results 201 to 210 of about 10,318 (317)

Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. [PDF]

J Endocr Soc
Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI.   +6 more
europepmc   +1 more source

GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study. [PDF]

BJUI Compass
Kwon S, Wardrop F, Gonzalez D, Ryan F, Khutsishvili L, Turner R, Deameh MG, Whalen MJ.   +7 more
europepmc   +1 more source

Poor Glycemic Control in East Africa: Prevalence, Risk Factors and Public Health Implications in Diabetes Management

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
In East Africa, poor glycaemic control is common (about 60%–85%), usually defined by HbA1c ≥ 7% (or > 7.5%) and sometimes fasting glucose. Older age, longer duration, comorbidities and barriers to adherence and access drive the burden—supporting tiered, access‐focused interventions.
Fanny Eseohe Onohuean, Mary Onohuean, Haron Olot, Hope Onohuean   +3 more
wiley   +1 more source

GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. [PDF]

J Clin Invest
Cardoso P, Dennis JM, Pearson ER.
europepmc   +1 more source

SAFETY OF GLP-1RA THERAPY: SIDE EFFECTS AND THE NEED FOR MONITORING [PDF]

Małgorzata Piasta, Miłosz Mandryk, Magdalena Grzesiak, Oskar Szymański   +3 more
openalex   +1 more source

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, Volume 7, Issue 2, Page 349-354, May 2026.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

GLP‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review

Alcohol, Clinical and Experimental Research, Volume 50, Issue 5, May 2026.
This narrative review of the development of GLP‐1 receptor agonists provides a foundation for both preclinical and clinical research on their use for treating alcohol use disorder (AUD). Both observational studies using real‐world data and randomized controlled clinical trials support the potential utility of these medications for treating AUD ...
Sean Woo, Grace Zhu, Chrismely Castro, Allen Phuong, Aadita Roy, Christal N. Davis, Henry R. Kranzler   +6 more
wiley   +1 more source

The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD Rats. [PDF]

Diabetes Metab Syndr Obes
Shao Y, Xu S, Ma Y, Zhang J, Guo X, Zhang T, Yuan G.   +6 more
europepmc   +1 more source

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes [PDF]

core   +1 more source

Depression following the initiation of glucagon‐like‐peptide‐1 receptor agonist therapy: A multinational self‐controlled case series study

Journal of Internal Medicine, Volume 299, Issue 6, Page 776-780, June 2026.
Vincent Ka Chun Yan, Zi‐Yang Peng, Vincent Kai Chung Wong, Ian Chi Kei Wong, Esther Wai Yin Chan, Huang‐Tz Ou, Eric Yuk Fai Wan   +6 more
wiley   +1 more source